IVA.PA - INVENTIVA
€3.32 -0.03 (-0.9%)
Updated: 11:49 May 5, 2024 ESTNext Session's AI Forecast
95.81%
Avg. Accuracy (AI)
€3.18
Next Week's AI Forecast
100%
Trend's Accuracy (AI)
€3.06
| Rank (0-100) |
| Rank (0-100) |
| Curr. Week | Curr. Month | Curr. Quarter | Next Quarter | Curr Year | 3.71 | -0.28 | -0.01 | -0.09 | 0.13 |
|---|
CURRENT VOLATILITY RANK
Variation from the lowest to the highest value in a period.
| Curr. Week | Curr. Month | Curr. Quarter | Next Quarter | Curr Year | 3.71 | 2.39 | 2.92 | 2.47 | 2.98 |
|---|
STOCHASTIC METRIC
The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.
| Curr. Week | Next Week | Curr. Month | Curr. Quarter | 100% | 100% | 54.84% | 42.86% |
|---|
MOVING AVERAGE METRIC
| 5 Sessions | Change 5 Sessions | 20 Sessions | Change 20 Sessions | 50 Sessions | Change 50 Sessions | 200 Sessions | 3.3 | 6.45% | 3.1 | -5.2% | 3.27 | -7.63% | 3.54 |
|---|
RSI METRIC
| RS Hour | RSI Hour | RS Day | RSI Day | 0.83 | 66.67 | 2 | 45.36 |
|---|
INVENTIVA Technical Analysis News
INVENTIVA
50 rue de Dijon
Daix 21121
France
33 3 80 44 75 00
https://www.inventivapharma.com
| Sectors: | Healthcare |
| Industry: | Biotechnology |
| F. Time Employees: | 120 |
Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
Corporate Governance
Inventiva S.A.’s ISS Governance QualityScore as of May 1, 2024 is 7. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 9; Compensation: 5.